TB/FLU-05E
Candidate Overview
TB/FLU-05E is a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. Vaccine formulation: Liquid nasal spray.
Sponsor / Lead Developer: Smorodintsev Research Institute of Influenza
Development partner(s): Federal State Unitary Enterprise “Scientific and Production Association for Immunological Preparations “Microgen” of the Ministry of Health of the Russian Federation
Clinical Trial Status: Active Trials
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB recurrence
Target Population(s): Adolescents, Adults, and Children
Target Route of Administration: Intranasal
Primary endpoint: Safety
Clinical Trials
ACTIVE TRIALS |
|
| Registry Number | NCTNCT05945498 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | Research Institute of Influenza |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
Related Publications
- Enhancement of the Local CD8+ T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens. (Vaccines (Basel), 2021).
- Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs. (Vaccines (Basel), 2021)